EORTC-QLQ-BR23 Clinical Workflow

Introduction

The BR-23 is a questionnaire for measuring the quality of life in patients with breast cancer, which was developed in 1996 [1].

The EORTC-QLQ-BR23 flow contains the EORTC-QLQ-BR23 questionnaire and associated calculation. After form submission, the EORTC-QLQ-BR23 calculation is executed automatically. It's easy to extend this flow with conditional logic based on the interpretation of the EORTC-QLQ-BR23 calculation.

EORTC-QLQ-BR23 questionnaire

Link to English version of the EORTC-QLQ-BR23.

BR23 is outdated - why an update was needed (BR23 to BR45)

In the last years many changes regarding treatment and diagnostics have occurred. For this reason the QLQ BR-23 was updated and 22 new questions were added. Now this new BR-45 questionnaire will be tested in patients with breast cancer in different countries [2].

The standard therapy of breast cancer has been changed, new therapies brought new side effects and different impacts on quality of life are not sufficiently covered by EORTC QLQ BR-23 which was developed in 1996. In Phase 1-3 the BR-23 Module was updated, 22 items were added, resulting in a new 45 item Module (EORTC QLQ BR-45). The aim of phase 4 is to test the psychometric properties and the validity of the EORTC QLQ-BR45 in conjunction with the EORTC QLQ-C30 in female patients diagnosed with breast cancer at different stages of the disease and with different therapy options.

References

[1] Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996 Oct;14(10):2756-68. doi: 10.1200/JCO.1996.14.10.2756. PMID: 8874337.\
[2] Bjelic-Radisic V, Cardoso F, Cameron D, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45 [published correction appears in Ann Oncol. 2020 Apr;31(4):552]. Ann Oncol. 2020;31(2):283-288. doi:10.1016/j.annonc.2019.10.027